Header Logo

Connection

Gary Raskob to Anticoagulants

Back to Details
This is a "connection" page, showing publications Gary Raskob has written about Anticoagulants.
Gary Raskob
Connection Strength
13.884
Anticoagulants
  1. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29; 406(10519):2551-2563.
    View in: PubMed
    Score: 0.812
  2. Anticoagulant Therapy for Mechanical Heart Valves - Unmet Need Persists. NEJM Evid. 2023 Jul; 2(7):EVIDe2300106.
    View in: PubMed
    Score: 0.689
  3. Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 02; 10(5):e019459.
    View in: PubMed
    Score: 0.585
  4. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
    View in: PubMed
    Score: 0.543
  5. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
    View in: PubMed
    Score: 0.505
  6. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
    View in: PubMed
    Score: 0.490
  7. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
    View in: PubMed
    Score: 0.469
  8. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2.
    View in: PubMed
    Score: 0.375
  9. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
    View in: PubMed
    Score: 0.368
  10. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
    View in: PubMed
    Score: 0.345
  11. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
    View in: PubMed
    Score: 0.280
  12. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13.
    View in: PubMed
    Score: 0.232
  13. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104.
    View in: PubMed
    Score: 0.231
  14. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12.
    View in: PubMed
    Score: 0.231
  15. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20.
    View in: PubMed
    Score: 0.179
  16. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S.
    View in: PubMed
    Score: 0.177
  17. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S.
    View in: PubMed
    Score: 0.177
  18. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229.
    View in: PubMed
    Score: 0.164
  19. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001 Nov 20; 135(10):858-69.
    View in: PubMed
    Score: 0.154
  20. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
    View in: PubMed
    Score: 0.154
  21. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
    View in: PubMed
    Score: 0.154
  22. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
    View in: PubMed
    Score: 0.152
  23. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
    View in: PubMed
    Score: 0.152
  24. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
    View in: PubMed
    Score: 0.151
  25. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
    View in: PubMed
    Score: 0.144
  26. Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med. 2000 Sep; 109(4):301-6.
    View in: PubMed
    Score: 0.142
  27. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
    View in: PubMed
    Score: 0.139
  28. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 01; 185:13-19.
    View in: PubMed
    Score: 0.134
  29. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
    View in: PubMed
    Score: 0.133
  30. Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. Curr Opin Pulm Med. 1999 Jul; 5(4):216-21.
    View in: PubMed
    Score: 0.131
  31. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
    View in: PubMed
    Score: 0.127
  32. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
    View in: PubMed
    Score: 0.126
  33. Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
    View in: PubMed
    Score: 0.122
  34. Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.
    View in: PubMed
    Score: 0.118
  35. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998; 28 Suppl 3:8-16.
    View in: PubMed
    Score: 0.118
  36. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
    View in: PubMed
    Score: 0.117
  37. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951.
    View in: PubMed
    Score: 0.117
  38. Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med. 1997 Nov 01; 127(9):839-41.
    View in: PubMed
    Score: 0.116
  39. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951.
    View in: PubMed
    Score: 0.115
  40. Duration of anticoagulant treatment for venous thrombosis. Curr Opin Pulm Med. 1997 Jul; 3(4):286-90.
    View in: PubMed
    Score: 0.114
  41. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793.
    View in: PubMed
    Score: 0.111
  42. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.
    View in: PubMed
    Score: 0.109
  43. Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
    View in: PubMed
    Score: 0.109
  44. Oral anticoagulant therapy. Curr Opin Hematol. 1996 Sep; 3(5):361-4.
    View in: PubMed
    Score: 0.107
  45. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med. 1996 Jul; 2(4):305-10.
    View in: PubMed
    Score: 0.106
  46. Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
    View in: PubMed
    Score: 0.105
  47. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61.
    View in: PubMed
    Score: 0.104
  48. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
    View in: PubMed
    Score: 0.104
  49. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
    View in: PubMed
    Score: 0.103
  50. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
    View in: PubMed
    Score: 0.101
  51. Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9.
    View in: PubMed
    Score: 0.100
  52. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76.
    View in: PubMed
    Score: 0.100
  53. Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Curr Opin Pulm Med. 1995 Jul; 1(4):291-7.
    View in: PubMed
    Score: 0.099
  54. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
    View in: PubMed
    Score: 0.095
  55. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
    View in: PubMed
    Score: 0.087
  56. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
    View in: PubMed
    Score: 0.086
  57. Long-term oral anticoagulant therapy for coronary artery disease. Haemostasis. 1993 Mar; 23 Suppl 1:32-41.
    View in: PubMed
    Score: 0.084
  58. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
    View in: PubMed
    Score: 0.084
  59. Hemorrhagic complications of anticoagulant treatment. Chest. 1992 Oct; 102(4 Suppl):352S-363S.
    View in: PubMed
    Score: 0.082
  60. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97.
    View in: PubMed
    Score: 0.079
  61. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
    View in: PubMed
    Score: 0.078
  62. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
    View in: PubMed
    Score: 0.077
  63. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036.
    View in: PubMed
    Score: 0.075
  64. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
    View in: PubMed
    Score: 0.072
  65. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
    View in: PubMed
    Score: 0.072
  66. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
    View in: PubMed
    Score: 0.071
  67. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
    View in: PubMed
    Score: 0.068
  68. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
    View in: PubMed
    Score: 0.066
  69. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30.
    View in: PubMed
    Score: 0.064
  70. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
    View in: PubMed
    Score: 0.064
  71. Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27.
    View in: PubMed
    Score: 0.063
  72. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
    View in: PubMed
    Score: 0.060
  73. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
    View in: PubMed
    Score: 0.059
  74. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505.
    View in: PubMed
    Score: 0.058
  75. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4.
    View in: PubMed
    Score: 0.057
  76. Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300.
    View in: PubMed
    Score: 0.053
  77. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S.
    View in: PubMed
    Score: 0.047
  78. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 04 07; 44(14):1231-1244.
    View in: PubMed
    Score: 0.042
  79. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96.
    View in: PubMed
    Score: 0.042
  80. Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
    View in: PubMed
    Score: 0.042
  81. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
    View in: PubMed
    Score: 0.040
  82. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002 Feb 25; 162(4):401-4.
    View in: PubMed
    Score: 0.039
  83. Abelacimab for Prevention of Venous Thromboembolism. Reply. N Engl J Med. 2021 11 04; 385(19):1822-1823.
    View in: PubMed
    Score: 0.038
  84. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017.
    View in: PubMed
    Score: 0.038
  85. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 11; 19(11):2801-2813.
    View in: PubMed
    Score: 0.038
  86. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
    View in: PubMed
    Score: 0.038
  87. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
    View in: PubMed
    Score: 0.038
  88. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S.
    View in: PubMed
    Score: 0.036
  89. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 02; 55(2).
    View in: PubMed
    Score: 0.034
  90. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
    View in: PubMed
    Score: 0.034
  91. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
    View in: PubMed
    Score: 0.034
  92. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999 Jan 25; 159(2):137-41.
    View in: PubMed
    Score: 0.032
  93. Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S.
    View in: PubMed
    Score: 0.031
  94. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12.
    View in: PubMed
    Score: 0.031
  95. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
    View in: PubMed
    Score: 0.030
  96. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997 Dec 8-22; 157(22):2562-8.
    View in: PubMed
    Score: 0.029
  97. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21.
    View in: PubMed
    Score: 0.029
  98. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
    View in: PubMed
    Score: 0.028
  99. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
    View in: PubMed
    Score: 0.028
  100. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
    View in: PubMed
    Score: 0.027
  101. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.
    View in: PubMed
    Score: 0.027
  102. Hemorrhagic complications of anticoagulant treatment. Chest. 1995 Oct; 108(4 Suppl):276S-290S.
    View in: PubMed
    Score: 0.025
  103. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
    View in: PubMed
    Score: 0.025
  104. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
    View in: PubMed
    Score: 0.024
  105. Preventing systemic embolism in patients with abnormal ventricular function. Cardiol Clin. 1994 Aug; 12(3):477-85.
    View in: PubMed
    Score: 0.023
  106. Diagnosis and management of pulmonary thromboembolism. Q J Med. 1990 Aug; 76(280):787-97.
    View in: PubMed
    Score: 0.018
  107. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989 Feb; 95(2 Suppl):26S-36S.
    View in: PubMed
    Score: 0.016
  108. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82.
    View in: PubMed
    Score: 0.014
  109. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1986 Feb; 89(2 Suppl):16S-25S.
    View in: PubMed
    Score: 0.013
  110. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am. 1986 Jan; 68(1):146-50.
    View in: PubMed
    Score: 0.013
  111. Risk of haemorrhage associated with long term anticoagulant therapy. Drugs. 1985 Nov; 30(5):444-60.
    View in: PubMed
    Score: 0.013
  112. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
    View in: PubMed
    Score: 0.010
  113. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000 Feb 01; 132(3):227-32.
    View in: PubMed
    Score: 0.009
  114. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
    View in: PubMed
    Score: 0.007
  115. Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6.
    View in: PubMed
    Score: 0.004
  116. Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.